How the 8 biggest U.S. pharmas enriched their shareholders in 2019
Thermo Fisher to help Civica Rx develop drugs the hospital group will own
FiercePharmaPolitics—After Jan. hikes, pricing remains the industry’s top concern in 2020: GlobalData
JPM: Glaxo’s cancer unit, in commercial ‘building mode,’ gets choosy with M&A
GlaxoSmithKline halts Excedrin production over manufacturing stumble
